{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-031701","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.153020+00:00","generated_at":"2026-05-14T22:04:34.233228+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.5,"confidence":"high","headline":"Zura Bio Q1 net loss $24.2M ($0.22/sh); advancing tibulizumab Phase 2 trials","bullets":["Net loss of $24.2M ($0.22 per share) vs. $17.4M ($0.19) in Q1 2025.","R&D expenses $14.7M, up from $10.5M, driven by tibulizumab Phase 2 programs.","Cash $225.6M as of March 31, 2026, expected to fund operations through at least end of 2028.","Phase 2 TibuSHIELD (HS) on track for topline data Q4 2026; TibuSURE (SSc) data expected H1 2027.","Completed $144M public offering in February 2026; appointed new CEO and two board members."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-031701","json":"https://secwatch.observer/filing/0001628280-26-031701.json","markdown":"https://secwatch.observer/filing/0001628280-26-031701.md","text":"https://secwatch.observer/filing/0001628280-26-031701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/0001628280-26-031701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/zura-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:04:34.233228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}